These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 11518066)
1. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort. Wonnemann M; Singer A; Siebert B; Müller WE Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S148-51. PubMed ID: 11518066 [TBL] [Abstract][Full Text] [Related]
2. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Butterweck V; Christoffel V; Nahrstedt A; Petereit F; Spengler B; Winterhoff H Life Sci; 2003 Jun; 73(5):627-39. PubMed ID: 12770617 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort: the role of amiloride sensitive sodium conductive pathways. Wonnemann M; Singer A; Müller WE Neuropsychopharmacology; 2000 Aug; 23(2):188-97. PubMed ID: 10882845 [TBL] [Abstract][Full Text] [Related]
4. Hyperforin as a possible antidepressant component of hypericum extracts. Chatterjee SS; Bhattacharya SK; Wonnemann M; Singer A; Müller WE Life Sci; 1998; 63(6):499-510. PubMed ID: 9718074 [TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro. Capasso R; Borrelli F; Capasso F; Mascolo N; Izzo AA Urology; 2004 Jul; 64(1):168-72. PubMed ID: 15245964 [TBL] [Abstract][Full Text] [Related]
6. Current St John's wort research from mode of action to clinical efficacy. Müller WE Pharmacol Res; 2003 Feb; 47(2):101-9. PubMed ID: 12543057 [TBL] [Abstract][Full Text] [Related]
7. In vitro binding studies with two hypericum perforatum extracts--hyperforin, hypericin and biapigenin--on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Gobbi M; Moia M; Pirona L; Morizzoni P; Mennini T Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S45-8. PubMed ID: 11518075 [TBL] [Abstract][Full Text] [Related]
8. Hyperforin--antidepressant activity by a novel mechanism of action. Müller WE; Singer A; Wonnemann M Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S98-102. PubMed ID: 11518085 [TBL] [Abstract][Full Text] [Related]
9. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Müller WE; Singer A; Wonnemann M; Hafner U; Rolli M; Schäfer C Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():16-21. PubMed ID: 9684943 [TBL] [Abstract][Full Text] [Related]
10. Hypericum perforatum L. (St John's wort) extract Ze 117 inhibits dopamine re-uptake in rat striatal brain slices. An implication for use in smoking cessation treatment? Ruedeberg C; Wiesmann UN; Brattstroem A; Honegger UE Phytother Res; 2010 Feb; 24(2):249-51. PubMed ID: 19585471 [TBL] [Abstract][Full Text] [Related]
11. [Cellular and molecular effects of the antidepressant hyperforin on brain cells: Review of the literature]. Bouron A; Lorrain E Encephale; 2014 Apr; 40(2):108-13. PubMed ID: 23816060 [TBL] [Abstract][Full Text] [Related]
12. In vitro photochemical and phototoxicological characterization of major constituents in St. John's Wort (Hypericum perforatum) extracts. Onoue S; Seto Y; Ochi M; Inoue R; Ito H; Hatano T; Yamada S Phytochemistry; 2011 Oct; 72(14-15):1814-20. PubMed ID: 21782201 [TBL] [Abstract][Full Text] [Related]
13. St. John's wort: role of active compounds for its mechanism of action and efficacy. Butterweck V; Schmidt M Wien Med Wochenschr; 2007; 157(13-14):356-61. PubMed ID: 17704987 [TBL] [Abstract][Full Text] [Related]
14. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort. Gödtel-Armbrust U; Metzger A; Kroll U; Kelber O; Wojnowski L Naunyn Schmiedebergs Arch Pharmacol; 2007 Aug; 375(6):377-82. PubMed ID: 17593354 [TBL] [Abstract][Full Text] [Related]
15. Effects of the antidepressant St. John's wort (Hypericum perforatum) on rat and human vas deferens contractility. Capasso R; Borrelli F; Montanaro V; Altieri V; Capasso F; Izzo AA J Urol; 2005 Jun; 173(6):2194-7. PubMed ID: 15879886 [TBL] [Abstract][Full Text] [Related]
16. Protective effects of St. John's wort extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic beta-cell line. Menegazzi M; Novelli M; Beffy P; D'Aleo V; Tedeschi E; Lupi R; Zoratti E; Marchetti P; Suzuki H; Masiello P Int J Biochem Cell Biol; 2008; 40(8):1509-21. PubMed ID: 18226577 [TBL] [Abstract][Full Text] [Related]
17. Role of hyperforin in the pharmacological activities of St. John's Wort. Zanoli P CNS Drug Rev; 2004; 10(3):203-18. PubMed ID: 15492771 [TBL] [Abstract][Full Text] [Related]
18. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Jensen AG; Hansen SH; Nielsen EO Life Sci; 2001 Feb; 68(14):1593-605. PubMed ID: 11263672 [TBL] [Abstract][Full Text] [Related]
19. Effects of a methanolic extract and a hyperforin-enriched CO2 extract of St. John's Wort (Hypericum perforatum) on intracerebral field potentials in the freely moving rat (Tele-Stereo-EEG). Dimpfel W; Schober F; Mannel M Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():30-5. PubMed ID: 9684945 [TBL] [Abstract][Full Text] [Related]
20. Extracts of St. John's wort and various constituents affect beta-adrenergic binding in rat frontal cortex. Simbrey K; Winterhoff H; Butterweck V Life Sci; 2004 Jan; 74(8):1027-38. PubMed ID: 14672758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]